Dendritic Cell and Tumor Cell Cancer Vaccines Market, 2016-2030

Dendritic Cell and Tumor Cell Cancer Vaccines Market, 2016-2030

Cancer is an extremely complex disease and medical science is still trying to understand the numerous factors responsible for its origin, propagation, spread (metastasis) and relapse. In 2016, an estimated 1.7 million new cancer cases were reported in the US alone. Furthermore, as projected by the World Health Organization (WHO), the annual incidence of cancer worldwide is expected to rise to 24 million by 2035. Currently, there is a huge unmet need for advanced and efficient treatment interventions for cancer. Standard approaches that are currently employed to treat cancer include surgery, radiation therapy and chemotherapy. Although all the three approaches are recognized as the current standard of care in cancer treatment, there are some risks and drawbacks associated with these methods.

Many pharmaceutical companies are working on identifying ways to improve these treatment methods, as well as develop new cancer therapies. One of the current focus areas is immunotherapy; it makes use of the body’s own immune system, or its components, to fight cancer. So far, antibody based therapeutics, including monoclonal antibodies (mAbs), bispecific antibodies (bsAbs) and antibody drug conjugates (ADCs), have had significant success as targeted anti-cancer therapies. Apart from antibody based therapies, there are other classes of immunotherapeutics that have been / are being developed to manage and treat cancer; these include immune checkpoint inhibitors (ICIs), therapeutic cancer vaccines and other whole cell based therapies.

The USFDA has approved cancer prevention vaccines (hepatitis B vaccine (HBV) and the human papillomavirus (HPV) vaccine) that prevent infection with cancer-causing viruses. Gardasil®, Gardasil 9® and Cervarix® are approved for the prevention of HPV-caused cancers whereas Engerix-B®, Recombivax HB®, Twinrix® and Pediarix® are approved for the prevention of chronic HBV infection. Although, preventive vaccines offer several benefits, the fact that viruses do not cause most cancers cannot be overlooked. Therefore, several companies are developing therapeutic vaccines that target specific cancers.

As of now, there are three marketed therapeutic cancer vaccines commercially available in different geographies; these are PROVENGE® (US), CreaVax-RCC® (South Korea) and TAPCells® (Chile). Despite the limited success of PROVENGE®, the first marketed dendritic cell vaccine, several stakeholders are actively engaged in the development of dendritic cell and tumor cell-based vaccines.

SCOPE OF THE REPORT
The Dendritic Cell and Tumor Cell Cancer Vaccines Market, 2016-2030 offers a comprehensive analysis of the current market landscape and future outlook of the growing pipeline of products in the therapeutic vaccines segment of the immuno-oncology domain. Currently, there are five types of such vaccines; these are dendritic cell vaccines, tumor cell vaccines, antigen / peptide vaccines, DNA vaccines and anti-idiotypic vaccines. This report is focused on the recent developments and the future potential of dendritic cell vaccines (dendritic cell loaded vaccines) and tumor cell vaccines (tumor cell loaded vaccines). Owing to the existing unmet demand for safe and effective cancer therapies and given the innate advantages of immunotherapies, we believe that dendritic cell and tumor cell cancer vaccines present lucrative opportunities for both therapy developers and investors alike.

During the course of our study, we identified a variety of dendritic cell and tumor cell cancer vaccines across various stages of development. More than 75% of these product candidates are currently in the clinical stages of development. With a rich development pipeline, this segment of the immunotherapy market has managed to capture the interest of several strategic investors and venture capital firms. During our research, we observed that over USD 1.5 billion has already been invested in this domain in past five years. Owing to the existing unmet demand for safe and effective cancer therapies and given the innate advantages of immunotherapies, we believe that dendritic cell and tumor cell cancer vaccines present lucrative opportunities for both therapy developers and investors alike.

One of the key objectives of the report was to understand the primary growth drivers and estimate the future size of the market. For this purpose, we took into consideration the following parameters:
The dendritic cell and tumor cell vaccines pipeline, including marketed, clinical and preclinical therapies, in terms of phase of development, key players, type of donor and target indications.
The existing and emerging technology platforms used for the development of innovative variants of cancer vaccines.
The partnerships that have taken place in the recent past covering clinical trial collaborations, research collaborations, manufacturing and services agreements, license agreements specific to technology platforms and agreements related to the co-development and co-commercialization of promising candidates.
Various investments and grants received by companies focused in this area including capital raised from IPOs and subsequent offerings.
The performance of competing drug classes, complex manufacturing processes, batch-wise variability and other inherent threats to growth of the market in the short and long term.

The report offers comprehensive profiles highlighting developmental history, clinical trial details and key clinical results as well as the future market opportunity for marketed and late stage (phase III) candidates. This opportunity is linked to the target consumer segments, likely adoption rate and expected pricing. We have provided an estimate of the size of the market in the short-mid-term and long term for the period between 2016 and 2030. The base year for the report is 2016. To account for the uncertainties associated with the development of novel therapeutic classes and to add robustness to our model, we have provided three forecast scenarios portraying the conservative, base, and optimistic tracks of the market’s evolution.

EXAMPLE HIGHLIGHTS
1. Over 60 dendritic cell and tumor cell cancer vaccines are currently in clinical / preclinical stages of development; 70% of the pipeline comprises of dendritic cell cancer vaccines.
2. 86% of the pipeline therapies are being developed as treatment options for solid tumors, including lung cancers, glioblastoma, prostate cancer and melanoma. In fact, two of the three marketed dendritic cell vaccines, PROVENGE® and TAPCells® (Chile), are approved for treatment of prostate cancer. In addition, a dendritic cell vaccine is also being developed as a first targeted therapy for the treatment of glioblastoma multiforme, the most common and aggressive form of brain cancer with poor survival rates.
3. The innovation in this emerging field is largely driven by smaller firms, specifically start-ups. Notable examples of small firms and start-ups include (in alphabetical order) Asterias Biotherapeutics, AVAX Technologies, DCPrime, Gradalis, Heat Biologics, ImmunoCellular Therapeutics, Immunicum, MolecuVax, Northwest Biotherapeutics, PDC*line Pharma, Pique Therapeutics, Regeneus, Tessa Therapeutics, Vaccinogen and XEME Biopharma. These companies have developed technology platforms that enhance the efficacy of therapeutic vaccines. Examples of some novel technology platforms include (in alphabetical order) AGGREGON™, DCOne®, ImPACT and Vigil®.
4. Several strategic investors and venture capitalists have strongly backed the potential offered by this domain. We identified over 125 instances of funding over the last few years. The total amount invested has been close to USD 2.0 billion; of this, USD 1.5 billion came during the last five years alone.
5. Several agreements have been inked amongst the stakeholders over past few years. We captured over 100 partnerships that are categorized across product development / commercialization agreement, manufacturing / supply agreement, service agreement, technology acquisition / licensing, clinical trial collaboration, research collaboration and others. Of these, clinical trial collaborations and technology acquisition / licensing together account for close to 50% share.
6. Prominent academic players, including (in alphabetical order) the Dana-Farber Cancer Institute, King’s College London, Mary Crowley Research Cancer Center, MD Anderson Cancer Center, University of Chile, and University of Pennsylvania, have entered into research collaborations with industry players to conduct further research for the improvement of existing therapies and the development of novel technologies.
7. Overall, the dendritic cell and tumor cell cancer vaccines market is expected to grow at a healthy annual rate of 20.7% till 2030. Dendritic cell vaccines are likely to garner the most attention in near future. Post 2020, we expect tumor cell vaccines to begin to actively contribute to the market’s revenues primarily driven by approval of Vigil®.

RESEARCH METHODOLOGY
Most of the data presented in this report has been gathered through secondary research. For most of our projects, we also conduct interviews with experts in the area (academia, industry, medical practice and other associations) to solicit their opinions on emerging trends in the market. This is primarily useful for us to draw out our own opinion on how the market will shape up across different regions and wearable types. Where possible, the available data has been checked for accuracy from multiple sources of information.

The secondary sources of information include:
Annual reports
Investor presentations
SEC filings
Industry databases
News releases from company websites
Government policy documents
Other analyst's opinion reports

While the focus has been on forecasting the market over the coming 14 years, the report also provides our independent view on various technological and non-commercial trends emerging in the industry. This opinion is solely based on our knowledge, research and understanding of the market developed from various secondary and primary sources of information.

CHAPTER OUTLINES
Chapter 2 provides an executive summary of the report. It offers a high level view on evolution of the dendritic cell and tumor cell cancer vaccines market in the mid to long term.

Chapter 3 provides information on the rising global burden of cancer and the various available therapeutic options. The chapter also includes a discussion on the emergence of immunotherapies and their advantages over current standard of care therapies.

Chapter 4 provides an introduction to cancer vaccines, including details on their history of development, respective mechanisms of action and the various challenges associated with their development and production. Further, the chapter includes brief overviews of the different types of cancer vaccines that are under development for the treatment of various oncological indications. It also includes a comprehensive compilation of the regulatory guidelines established to monitor, manage and regulate the development of therapeutic cancer vaccines.

Chapter 5 features a detailed and comprehensive analysis of the current market landscape of dendritic cell and tumor cell cancer vaccines. It includes information, such as the target indications, current phase of development, the type of donor and the type of vaccines, on the various marketed and pipeline therapies.

Chapter 6 contains a detailed discussion on dendritic cell cancer vaccines. The chapter includes detailed profiles of the marketed and phase III vaccines in this category. Each profile contains a brief discussion on the history of development of the particular therapy, its mechanism of action, dosage regimen, information on its clinical trials and key clinical insights. Further, the profiles provide details on the developer, including financial information, existing intellectual property, current product portfolio and manufacturing capabilities.

Chapter 7 provides a detailed discussion on tumor cell cancer vaccines. Similar to Chapter 6, the chapter also includes comprehensive profiles of the phase III tumor cell cancer vaccines. Each profile covers information such as the history of development of a particular therapy, its mechanism of action, dosage regimen, information on clinical trials and key clinical results. Further, it provides information about the developer as well, including details on financials, existing intellectual property, product portfolio and manufacturing facilities. In addition, this chapter consists of a case study on NewLink Genetics and its portfolio of products based on the HyperAcute® technology.

Chapter 8 includes a detailed discussion on the various technology platforms that are currently being used for the development of dendritic cell and tumor cell cancer vaccines.

Chapter 9 presents a detailed study of the investments made in this domain. The funding instances captured in the chapter include venture capital financing, public offerings, grants and other forms of equity / debt financing. The analysis highlights the growing interest of the VC community and other strategic investors in this segment of the immunotherapy market.

Chapter 10 features a comprehensive analysis of the collaborations and partnerships that have been forged between the players in this market. In the chapter, we have discussed the various types of partnership models that are employed by stakeholders in this domain. We have also categorized the deals / agreements, which we came across during our research, based on the aforementioned models and provided our reviewed the trend of partnerships over time.

Chapter 11 presents a detailed market forecast for dendritic cell and tumor cell cancer vaccines and a discussion on the overall financial opportunity that exists in this domain. It includes future sales projections for molecules in advanced stages of development. These projections took into account the target patient population, the existence of competing drugs or drug classes, likely adoption rate and the expected price of each individual therapy.

Chapter 12 provides a summary of the overall report. In this chapter, we present a list of key takeaways from the report and our independent opinion on the nature and potential of the cancer vaccines market. The insights presented in this chapter are based on the research and analysis described in the previous chapters.

Chapter 13 contains a collection of interview transcripts of discussions held with some of the key players in the industry.

Chapters 14 and 15 are appendices, which provide tabulated data and a list of companies mentioned in the report, respectively.

LIST OF COMPANIES AND ORGANIZATIONS

The following companies and organizations have been mentioned in the study.
1. Abramson Cancer Center
2. Accelovance
3. Accord Research
4. Activartis Biotech
5. Adaptive Biotechnologies
6. Aduro Biotech
7. Alliance Foundation Trials (AFT)
8. American International Radio
9. American Red Cross Society
10. Ames Seed Capital
11. Amphera
12. Aptiv Solutions
13. Argos Therapeutics
14. Artwell Biotech
15. Aspire Capital
16. Asset Management Ventures
17. Asterias Biotherapeutics
18. Aurora BioPharma
19. Aurora Funds
20. AVAX Technologies
21. Bar Elan University of Israel
22. Basic Pharma
23. Baylor College of Medicine (BCM)
24. Beijing Tricision Biotherapeutics
25. Benitec Biopharma
26. Beth Israel Deaconess Medical Centre
27. BioLife Solutions
28. Biomira
29. BioSante Pharmaceuticals
30. BioTime
31. BioTime Acquisition
32. Brightline Ventures
33. Bristol-Myers Squibb
34. Bundang CHA General Hospital
35. Caisse de dépôt et placement du Québec
36. Caladrius BioSciences
37. Caliber Biotherapeutics
38. California Institute for Regenerative Medicine (CIRM)
39. California Institute of Technology
40. Canadian Brain Tumour Consortium (CBTC)
41. Cancer Research Technology (CRT)
42. CANCER RESEARCH UK
43. Cancer Treatment Centers of America (CTCA)
44. Cascadian Therapeutics
45. Cedars-Sinai Medical Centre
46. Cell Therapy Catapult
47. Celldex Therapeutics
48. Cellin Technologies
49. CELLMED Research
50. Champions Biotechnology
51. Charles University
52. Chicagoland Investors
53. Chiltern International
54. China BioPharma Capital I
55. Chongqing Lummy Pharmaceutical
56. CiMaas
57. City of Hope Comprehensive Cancer Center
58. Clinipace Worldwide
59. Clough Capital Partners
60. Cognate Bioservices
61. CORFO
62. CruCell
63. CryoPort
64. CyTuVax
65. Dana Farber Cancer Center
66. DanDrit Biotech
67. Danube Hospital Vienna
68. DCPrime
69. Delta-Vir
70. Dendreon Corporation
71. Department of Defense (CDMRP)
72. Department of Immunology of the 2nd Medical School of Charles University
73. Dong-A ST
74. Drexel University
75. Duke University
76. Dutch Ministry of Health, Welfare and Sports
77. Ehime University Hospital
78. Elios Therapeutics
79. Emperor Franz-Josef Hospital Vienna
80. ES Cell International Pte
81. European Medicines Agency (EMA)
82. European Organization for Research and Treatment of Cancer (EORTC)
83. Feldkirch State Hospital
84. Ferrer International
85. FONNDEF
86. Forbion Capital
87. Foresite Capital Management
88. Franklin Advisers
89. Fraunhofer Institute for Cell Therapy and Immunology
90. FUJIFILM Diosynth Biotechnologies
91. Genentech
92. Geron Corporation
93. GISCAD Foundation
94. Gradalis
95. Green Cross Corporation
96. GSK
97. Guangzhou Trinomab Biotech
98. Hakutokai Takao Hospital
99. Heat Biologics
100. Horizon Technology Finance Corporation
101. ICON
102. Immatics Biotechnologies
103. Immunicum
104. ImmunoCellular Therapeutics
105. Immunotherapy of Cancer (ITOC)
106. Innovation Agency
107. Innsbruck Medical University
108. Institute for Quality and Efficiency in Health Care (IQWiG)
109. Institute of Inorganic Chemistry and the Institute of Chemistry of Polymers
110. Intersouth Partners
111. Intracel Corporation
112. Invetech
113. Iowa Economic Development Authority (IEDA)
114. Iowa State University Research Park Corporation (ISURP)
115. Janssen Pharmaceuticals
116. Janus Capital Management
117. Jennison Associates
118. Jikei University School of Medicine
119. Johannes Kepler University Linz
120. Johns Hopkins University (JHU)
121. Johnson & Johnson Development Corporation (JJDC)
122. JW CreaGene
123. Karolinska University Hospital
124. King’s College Hospital
125. Kirin Brewery Pharmaceutical Division
126. Kiromic
127. Kitasato Institute Hosptital
128. Kyowa Hakko Kirin
129. Laboratorio Pablo Cassara
130. Leaders in Oncology Care (LOC)
131. Lumira Capital
132. Maastricht University Medical Centre
133. Mary Crowley Cancer Research Center
134. Masarik University Brno
135. Massachusetts Biotechnology Council (MassBio)
136. Maxim Group
137. Mayo Clinic
138. MD Anderson Cancer Centre
139. Medical Corporation Hakutokai
140. Medical Corporation Isokai
141. Medical School of Charles University
142. Medical University of Graz
143. Medical University of Hannover
144. Medical University of Vienna
145. Medigene Immunotherapies
146. Medinet
147. Merck
148. Merix Bioscience
149. Midwest Melanoma Partnership (MMP)
150. Mizuho capital
151. MNX Global Logistics
152. MolecuVax
153. Morningside Group
154. Morningside Ventures
155. National Cancer Institute
156. National Center for Global Health and Medicine
157. National Center for Global Health and Medicine
158. National Health Service (NHS)
159. National Institute for Health and Care Excellence (NICE)
160. National Institutes of Health (NIH)
161. National University Corporation Kyushu University
162. National University of Singapore (NUS)
163. NeoStem
164. Neovii Biotech
165. NewLink Genetics
166. Northwest Biotherapeutics
167. Novartis
168. NovaRx Corporation
169. Novella Clinical
170. Oncobiomed
171. OncoSec Medical
172. Oncothyreon
173. OrbiMed
174. Oxford Finance
175. Pan Am Cancer Treatment Center
176. Paul Ehrlich Institute (PEI)
177. PDC*line pharma
178. PerImmune
179. Pfizer
180. PharmaCell
181. Pharmacenter Hungary
182. Pharmstandard International
183. Piedmont Angel Network
184. Pique Therapeutics
185. PPF Group
186. Prima BioMed
187. Progenitor Cell Therapy (PCT)
188. ProImmune
189. ProVaccine
190. Pure MHC
191. Regeneus
192. Research Center for Molecular Medicine of the Austrian Academy of Sciences
193. RimAsia Capital Partners
194. Roche
195. Rockefeller University
196. Rudolfstiftung Hospital Vienna
197. Sächsische Aufbau Bank
198. Sahlgrenska University Hospital
199. Saint-Gobain
200. Salzburg Provincial Hospital
201. Sarah Cannon Research UK
202. Saronic Biotechnology
203. School of Medicine of Keio University
204. Scottish Medicines Consortium
205. SDS Capital
206. Shenzhen Hornetcorn Bio-technology Company
207. Significo Research
208. SIGNIFIX
209. Socius Life Sciences Capital Group
210. SOTIO
211. Square 1 Bank
212. St. Anna Children's Cancer Research
213. Stanford University
214. State Institute for Drug Control
215. Swissmedic
216. Sydys Corporation
217. TapImmune
218. Targepeutics
219. Technomark Life Sciences
220. tella
221. Tessa Therapeutics
222. The Immune Response Corporation
223. The Investment Syndicate (TIS)
224. The Vaccine & Gene Therapy Institute of Florida (VGTI)
225. Theradex
226. Therapeutic Solutions International
227. TheraTest Laboratories
228. TI Pharma
229. Tianyi Lummy International Holdings Group
230. Torrey Pines Institute for Molecular Studies
231. TransCure bioServices
232. Trianta Immunotherapies
233. TVAX Biomedical
234. TVM Capital
235. UCB
236. United States Food and Drug Administration (USFDA)
237. United Therapeutics
238. UniVax
239. University Hospital Motol of Prague
240. University of British Columbia
241. University of Chile
242. University of Maryland
243. University of Minnesota
244. University of Pennsylvania
245. University of Pittsburgh
246. University of Southern California
247. University of Texas
248. University of Zurich Medical School
249. Uppsala University
250. US Patent and Trademark Office (USPTO)
251. Vaccinogen
252. Valeant Pharmaceuticals
253. Van Herk Group
254. Västra Götalandsregionen
255. Wagner-Jauregg Linz
256. Wasatch Funds Trust
257. Wilmington Investors Network
258. Woodford Investment Management
259. WuXi AppTec
260. XEME Biopharma


1. PREFACE
1.1. Scope of the Report
1.2. Research Methodology
1.3. Chapter Outlines
2. EXECUTIVE SUMMARY
3. INTRODUCTION
3.1. Cancer: An Overview
3.2. Current Statistics and Global Burden of the Disease
3.3. The Four Pillars of Cancer Therapy
3.4. Immunotherapy: Gaining Strong Foothold
3.5. Classification of Cancer Immunotherapies
3.5.1. By Mechanism of Action
3.5.2. By Type of Target
3.5.3. By Approach
3.5.4. By Product Class
3.5.4.1. Therapeutic Antibodies
3.5.4.1.1. Monoclonal Antibodies
3.5.4.1.2. Bispecific Antibodies
3.5.4.1.3. Antibody Drug Conjugates
3.5.4.1.4. Engineered Antibodies
3.5.4.2. Cytokines
3.5.4.3. Cell Based Therapies
3.5.4.4. Immune Checkpoint Inhibitors
3.5.4.5. Cancer Vaccines
4. CANCER VACCINES
4.1. Vaccines: An Overview
4.2. Cancer Vaccines: An Overview
4.2.1. Cancer Vaccines: History of Development
4.2.2. Tumor Evasion from Immune Surveillance
4.2.3. Potential Targets
4.3. Types of Cancer Vaccines
4.3.1. Classification Based on Type of Cancer Vaccine
4.3.1.1. Prophylactic (Preventive) Vaccines
4.3.1.2. Therapeutic (Treatment) Vaccines
4.3.2. Classification Based on Type of Donor
4.3.2.1. Autologous Cancer Vaccines
4.3.2.2. Allogeneic Cancer Vaccines
4.3.3. Classification Based on Composition
4.3.3.1. Antigen Vaccines
4.3.3.2. Anti- Idiotypic Vaccines
4.3.3.3. DNA Vaccines
4.3.3.4. Dendritic Cell Vaccines
4.3.3.5. Tumor Cell Vaccines
4.4. Challenges Associated with Cancer Vaccines
4.5. Regulatory Guidelines for Therapeutic Cancer Vaccines
4.5.1. Considerations for All Three Clinical Trial Phases
4.5.1.1. Selection of Patient Population on the Basis of Disease Setting, Tumor Heterogeneity and Target Antigen
4.5.1.2. Monitoring the Immune Response
4.5.1.3. Progression / Recurrence of the Disease Post Treatment with Cancer Vaccines
4.5.2. Considerations for Early Clinical Trials
4.5.2.1. Starting Dose and Dosing Schedule
4.5.2.2. Dose Escalation
4.5.2.3. Single-arm versus Randomized Phase II Trials
4.5.3. Considerations for Late Phase Clinical Trials
4.5.3.1. Safety Profile from Early Phase Clinical Trials
4.5.3.2. Endpoints
4.5.3.3. Superiority Versus Non- Inferiority Design
4.5.3.4. Selection of Control
4.5.3.5. Delayed Vaccine Effect
4.5.3.6. Autologous Vaccine Trials
4.5.4. Accelerated Approval Regulations
5. MARKET OVERVIEW
5.1. Chapter Overview
5.2. Dendritic Cell and Tumor Cell Cancer Vaccines: A Robust Pipeline
5.3. Pipeline Analysis
5.3.1. Cancer Vaccines: Distribution by Type of Cancer Vaccine
5.3.2. Cancer Vaccines: Distribution by Phase of Development
5.3.3. Cancer Vaccines: Distribution by Type of Oncological Indication
5.3.3.1. Cancer Vaccines: Distribution by Hematological Cancers
5.3.3.2. Cancer Vaccines: Distribution by Non-Hematological Cancers
5.3.4. Cancer Vaccines: Distribution by Type of Donor
6. DENDRITIC CANCER CELL VACCINES
6.1. Chapter Overview
6.2. Dendritic Cell Cancer Vaccines: An Introduction
6.3. Dendritic Cell Cancer Vaccines: Mechanism of Action
6.4. Dendritic Cell Cancer Vaccines: Pipeline
6.5. Dendreon Corporation (A Subsidiary of Valeant Pharmaceuticals)
6.5.1. Company Overview
6.5.2. Financial Performance
6.5.3. Technology Overview
6.5.3.1. Antigen Delivery Cassette® Technology
6.5.4. Patent Portfolio
6.5.5. Manufacturing Facilities
6.5.6. Product Portfolio
6.5.6.1. PROVENGE® / Sipuleucel-T
6.5.6.1.1. Product Overview
6.5.6.1.2. History of Development
6.5.6.1.3. Dosage Regimen
6.5.6.1.4. Historical Sales
6.5.6.1.5. Treatment Cost and Reimbursement
6.5.6.1.6. Current Status of Development
6.5.6.1.7. Clinical Trials
6.5.6.1.8. Key Clinical Trial Results
6.6. JW CreaGene
6.6.1. Company Overview
6.6.2. Technology Overview
6.6.2.1. DC Technology
6.6.3. Patent Portfolio
6.6.4. Product Portfolio
6.6.4.1. CreaVax-RCC®
6.6.4.1.1. Product Overview
6.6.4.1.2. Dosage Regimen
6.6.4.1.3. Clinical Trials
6.6.4.2. CreaVax-HCC
6.6.4.2.1. Product Overview
6.6.4.2.2. Current Status of Development
6.6.4.2.3. Clinical Trials
6.7. Oncobiomed
6.7.1. Company Overview
6.7.2. Technology Overview
6.7.2.1. TAPCells® Technology
6.7.3. Patent Portfolio
6.7.4. Product Portfolio
6.7.4.1. TAPCells®
6.7.4.1.1. Product Overview
6.7.4.1.2. Dosage Regimen
6.7.4.1.3. Clinical Trials
6.8. Argos Therapeutics
6.8.1. Company Overview
6.8.2. Financial Performance
6.8.3. Technology Overview
6.8.3.1. Arcelis® Technology
6.8.4. Patent Portfolio
6.8.5. Manufacturing Facilities
6.8.6. Product Portfolio
6.8.6.1. AGS-003
6.8.6.1.1. Product Overview
6.8.6.1.2. History of Development
6.8.6.1.3. Dosage Regimen
6.8.6.1.4. Current Status of Development
6.8.6.1.5. Clinical Trials
6.8.6.1.6. Key Clinical Trial Results
6.9. ImmunoCellular Therapeutics
6.9.1. Company Overview
6.9.2. Financial Performance
6.9.3. Technology Overview
6.9.3.1. Dendritic Cell (DC)-Based Immunotherapy
6.9.3.2. Stem-to-T-cell Program
6.9.4. Patent Portfolio
6.9.5. Manufacturing Facilities
6.9.6. Product Portfolio
6.9.6.1. ICT-107
6.9.6.1.1. Product Overview
6.9.6.1.2. History of Development
6.9.6.1.3. Dosage Regimen
6.9.6.1.4. Current Status of Development
6.9.6.1.5. Clinical Trials
6.9.6.1.6. Key Clinical Trial Results
6.10. Northwest Biotherapeutics
6.10.1. Company Overview
6.10.2. Financial Performance
6.10.3. Technology Overview
6.10.3.1. DCVax® Technology
6.10.4. Patent Portfolio
6.10.5. Manufacturing Facilities
6.10.6. Product Portfolio
6.10.6.1. DCVax®-L
6.10.6.1.1. Product Overview
6.10.6.1.2. History of Development
6.10.6.1.3. Dosage Regimen
6.10.6.1.4. Current Status of Development
6.10.6.1.5. Clinical Trials
6.10.6.1.6. Key Clinical Trial Results
6.11. SOTIO (Acquired by PPF Group)
6.11.1. Company Overview
6.11.2. Financial Performance
6.11.3. Technology Overview
6.11.3.1. Active Cellular Immunotherapy Multiple Antigen Presentation
6.11.4. Patent Portfolio
6.11.5. Manufacturing Facilities
6.11.6. Product Portfolio
6.11.6.1. DCVAC/PCa
6.11.6.1.1. Product Overview
6.11.6.1.2. History of Development
6.11.6.1.3. Dosage Regimen
6.11.6.1.4. Current Status of Development
6.11.6.1.5. Clinical Trials
6.11.6.1.6. Key Clinical Results
6.12. Dendritic Cell Cancer Vaccines: Key Drivers and Restraints
7. TUMOR CELL CANCER VACCINES
7.1. Chapter Overview
7.2. Tumor Cell Cancer Vaccines: An Overview
7.3. Tumor Cell Cancer Vaccines: Mechanism of Action
7.4. Tumor Cell Cancer Vaccines: Pipeline
7.5. Vaccinogen
7.5.1. Company Overview
7.5.2. Financial Performance
7.5.3. Technology Overview
7.5.3.1. OncoVAX® Technology Platform
7.5.3.2. HuMabs
7.5.3.3. DiCAST
7.5.4. Patent Portfolio
7.5.5. Manufacturing Facilities
7.5.6. Product Portfolio
7.5.6.1. OncoVAX®
7.5.6.1.1. Product Overview
7.5.6.1.2. History of Development
7.5.6.1.3. Production Process
7.5.6.1.4. Dosage Regimen
7.5.6.1.5. Current Status of Development
7.5.6.1.6. Clinical Trials
7.5.6.1.7. Key Clinical Trial Results
7.6. Gradalis
7.6.1. Company Overview
7.6.2. Technology Overview
7.6.2.1. Vigil® Platform
7.6.3. Patent Portfolio
7.6.4. Product Portfolio
7.6.4.1. Vigil®
7.6.4.1.1. Product Overview
7.6.4.1.2. History of Development
7.6.4.1.3. Production Process
7.6.4.1.4. Dosage Regimen
7.6.4.1.5. Current Status of Development
7.6.4.1.6. Clinical Trials
7.6.4.1.7. Key Clinical Trial Results
7.7. Case Study: HyperAcute Cellular Immunotherapy
7.7.1. NewLink Genetics
7.7.1.1. Company Overview
7.7.1.2. Financial Performance
7.7.1.3. Technology Overview
7.7.1.3.1. HyperAcute® Cellular Immunotherapy
7.7.1.4. Patent Portfolio
7.7.1.5. Manufacturing Facilities
7.7.1.6. Product Portfolio
7.7.1.6.1. Algenpantucel- L
7.7.1.6.2. Tergenpumatucel-L
7.8. Tumor Cell Vaccines: Drivers and Restraints
8. KEY TECHNOLOGIES
8.1. Chapter Overview
8.2. Asterias Biotherapeutics
8.2.1. Company Overview
8.2.2. Technology Platforms
8.2.2.1. Asterias’ Cell Therapy Platform
8.2.2.2. Pluripotent Stem Cell Platform
8.2.3. Pipeline
8.3. AVAX Technologies
8.3.1. Company Overview
8.3.2. Technology Platforms
8.3.2.1. Autologous Cell (AC) Vaccine® Technology
8.3.3. Pipeline
8.4. DCPrime
8.4.1. Company Overview
8.4.2. Technology Platforms
8.4.2.1. DCOne®
8.4.3. Pipeline
8.5. Heat Biologics
8.5.1. Company overview
8.5.2. Technology Platforms
8.5.2.1. ImPACT
8.5.2.2. ComPACT
8.5.3. Pipeline
8.6. Immunicum
8.6.1. Company Overview
8.6.2. Technology Platforms
8.6.2.1. COMBIG
8.6.2.1.1. INTUVAX®
8.6.2.1.2. SUBCUVAX®
8.6.3. Pipeline
8.7. XEME Biopharma
8.7.1. Company Overview
8.7.2. Technology Platforms
8.7.2.1. AGGREGON™
8.7.3. Pipeline
9. VENTURE CAPITAL FUNDING
9.1. Chapter Overview
9.2. Types of Funding
9.3. Cancer Vaccines Market: Funding Instances
9.4. Cancer Vaccines Market: Rising Venture Capital Interest
9.5. Distribution of Funding Instances by Type of Funding
9.6. Leading Players: Distribution by Number of Funding Instances
9.7. Cancer Vaccines: Analysis by Type of Investment and Amount Invested
10. PARTNERSHIPS AND COLLABORATIONS
10.1. Chapter Overview
10.2. Partnerships Models / Agreements
10.3. Cancer Vaccines: List of Partnerships
10.4. Cancer Vaccines: Growing Trend of Partnerships
11. MARKET FORECAST
11.1. Chapter Overview
11.2. Scope and Limitations
11.3. Forecast Methodology
11.4. Overall Cancer Vaccines Market, 2016 - 2030
11.4.1. Overall Cancer Vaccines Market: Distribution by Type of Vaccine
11.5. Individual Therapy Forecast
11.5.1. PROVENGE® (Dendreon Corporation / Valeant Pharmaceuticals)
11.5.1.1. Target Patient Population
11.5.1.2. Sales Forecast
11.5.2. DCVax®-L / DCVax-Brain (Northwest Biotherapeutics)
11.5.2.1. Target Patient Population
11.5.2.2. Sales Forecast
11.5.3. AGS-003 (Argos Therapeutics)
11.5.3.1. Target Patient Population
11.5.3.2. Sales Forecast
11.5.4. DCVAC/PCa (SOTIO)
11.5.4.1. Target Patient Population
11.5.4.2. Sales Forecast
11.5.5. Vigil® (Gradalis)
11.5.5.1. Target Patient Population
11.5.5.2. Sales Forecast
11.5.6. AST-VAC1 / GRNVAC1 (Asterias Biotherapeutics)
11.5.6.1. Target Patient Population
11.5.6.2. Sales Forecast
11.5.7. M-VAX (AVAX Technologies)
11.5.7.1. Target Patient Population
11.5.7.2. Sales Forecast
11.5.8. ICT-107 (ImmunoCellular Therapeutics)
11.5.8.1. Target Patient Population
11.5.8.2. Sales Forecast
11.5.9. OncoVAX® (Vaccinogen)
11.5.9.1. Target Patient Population
11.5.9.2. Sales Forecast
11.5.10. MX-225 (Aurora Biopharma)
11.5.10.1. Target Patient Population
11.5.10.2. Sales Forecast
12. CONCLUSION
12.1. A Robust Pipeline Dominated by Dendritic Cell Vaccine Candidates
12.2. Allogeneic Off-the-Shelf Vaccines Being Developed to Overcome Manufacturing Challenges Associated with Personalized Autologous Therapies
12.3. An Active Market Segment Primarily Driven by Start-Ups and Small Companies
12.4. Broad Spectrum Therapies that are Currently Focused Mainly on Lung Cancer and Melanoma
12.5. Innovative Technology Platforms are a Key Enabler
12.6. Lucrative Future Opportunity Despite the Limited Success of Currently Marketed Therapies
13. INTERVIEW TRANSCRIPTS
14. APPENDIX: TABULATED DATA
15. APPENDIX: LIST OF COMPANIES AND ORGANIZATIONS
LIST OF FIGURES
Figure 3.1 Global Cancer Incidence: Distribution by Type of Cancer
Figure 3.2 Lung Cancer: Estimated New Cases in 2015 (Thousands)
Figure 3.3 Breast Cancer: Estimated New Cases in 2015 (Thousands)
Figure 3.4 Colorectal Cancer: Estimated New Cases in 2015 (Thousands)
Figure 3.5 The Four Pillars of Cancer Therapy
Figure 3.6 Differences between Active and Passive Immunotherapy
Figure 3.7 Differences between Specific and Non-Specific Immunotherapy
Figure 3.8 Components of ADCs
Figure 4.1 APC-T-cell Interaction: Fate of T-cells
Figure 4.2 Cancer Vaccines: Historical Milestones
Figure 4.3 Interaction between Tumor Cells and the Immune System
Figure 5.1 Cancer Vaccines: Distribution by Type of Vaccine
Figure 5.2 Cancer Vaccines: Distribution by Phase of Development
Figure 5.3 Cancer Vaccines: Distribution by Phase of Development (Marketed / PIII / PII / PI / Preclinical)
Figure 5.4 Cancer Vaccines: Distribution by Therapeutic Area
Figure 5.5 Cancer Vaccines: Distribution by Hematological Cancers and Type of Vaccine
Figure 5.6 Cancer Vaccines: Distribution by Non-Hematological Cancers and Type of Vaccine
Figure 5.7 Cancer Vaccines: Distribution by Type of Donor
Figure 6.1 Stages of Immunostimulation by Dendritic Cells
Figure 6.2 Dendreon Corporation: Revenues, 2010-2013 (USD Million)
Figure 6.3 PROVENGE: Historical Timeline
Figure 6.4 PROVENGE: Historical Sales, 2011-2015 (USD Million)
Figure 6.5 Argos Therapeutics: Revenues, 2012-2016 (USD Million)
Figure 6.6 Argos Therapeutics: Funding Instances
Figure 6.7 AGS-003: Historical Timeline
Figure 6.8 ImmunoCellular Therapeutics: Funding Instances (USD Million)
Figure 6.9 DC-based Immunotherapeutics: Manufacturing Process
Figure 6.10 ICT-107: Historical Timeline
Figure 6.11 Northwest Biotherapeutics: Revenue, 2011-2015 (USD Million)
Figure 6.12 Northwest Biotherapeutics: Funding Instances (USD Million)
Figure 6.13 DCVax-L: Historical Timeline
Figure 6.14 PPF Group: Revenues, 2011-2015 (EUR Billion)
Figure 6.15 DCVAC/PCa: Historical Timeline
Figure 6.16 Dendritic Cell Cancer Vaccines: Key Drivers and Restraints
Figure 7.1 Vaccinogen: Funding Instances (USD Million)
Figure 7.2 OncoVAX: Historical Timeline
Figure 7.3 OncoVAX: Production Process
Figure 7.4 OncoVAX: Dosage Regimen
Figure 7.5 Vigil: Historical Timeline
Figure 7.6 NewLink Genetics: Revenues, 2012-2016 (USD Million)
Figure 7.7 NewLink Genetics: Funding Instances (USD Million)
Figure 7.8 Algenpantucel- L: Historical Timeline
Figure 7.9 Tumor Cell Cancer Vaccines: Key Drivers and Restraints
Figure 8.1 DCOne: Key Steps Involved
Figure 8.2 AGGREON: Proposed Mechanism of Action
Figure 9.1 Cumulative Funding Instances, Pre-2009-2016
Figure 9.2 Cumulative Funding Amount, Pre-2009-2016 (USD Million)
Figure 9.3 Funding Instances: Distribution by Type, Pre-2009-2016
Figure 9.4 Funding Instances: Distribution by Total Amount Invested, Pre-2009-2016 (USD Million)
Figure 9.5 Leading Players: Distribution by Number of Funding Instances
Figure 9.6 Funding Instances: Distribution by Amount Invested by Type of Funding (USD Million)
Figure 10.1 Cancer Vaccines: Cumulative Trend of Partnerships (Pre-2010-2016)
Figure 10.2 Cancer Vaccines: Distribution by Type of Partnership
Figure 10.3 Cancer Vaccines: Leading Players by Partnerships
Figure 11.1 Overall Dendritic Cell and Tumor Cell Cancer Vaccines Market (USD Million), 2016-2030
Figure 11.2 Overall Dendritic Cell and Tumor Cell Cancer Vaccines Market: Distribution by Type of Cancer Vaccine (USD Million), 2016-2030
Figure 11.3 Evolution of Dendritic Cell and Tumor Cell Cancer Vaccine Market: 2020, 2025 & 2030 (Base Scenario)
Figure 11.4 PROVENGE Sales Forecast, 2016-2030: Base Scenario (USD Million)
Figure 11.5 DCVax-L Sales Forecast, 2017-2030: Base Scenario (USD Million)
Figure 11.6 AGS-003 Sales Forecast, 2018-2030: Base Scenario (USD Million)
Figure 11.7 DCVAC/PCa Sales Forecast, 2020-2030: Base Scenario (USD Million)
Figure 11.8 Vigil Sales Forecast, 2021-2030: Base Scenario (USD Million)
Figure 11.9 AST-VAC1 Sales Forecast, 2022-2030: Base Scenario (USD Million)
Figure 11.10 M-VAX Sales Forecast, 2022-2030: Base Scenario (USD Million)
Figure 11.11 ICT-107 Sales Forecast, 2023-2030: Base Scenario (USD Million)
Figure 11.12 OncoVAX Sales Forecast, 2025-2030: Base Scenario (USD Million)
Figure 11.13 MX-225 Sales Forecast, 2026-2030: Base Scenario (USD Million)
Figure 12.1 Dendritic Cell and Tumor Cell Cancer Vaccines: Development Landscape
Figure 12.2 Dendritic Cell Cancer Vaccines: Developer Landscape
Figure 12.3 Tumor Cell Cancer Vaccines: Developer Landscape
Figure 12.4 Dendritic Cell and Tumor Cell Cancer Vaccines: Analysis by Cancer Type
Figure 12.5 Dendritic Cell and Tumor Cell Cancer Vaccines: Technology Landscape
Figure 12.6 Dendritic Cell and Tumor Cell Cancer Vaccines Market: Conservative, Base and Optimistic Forecast Scenarios, 2016-2030 (USD Million)
LIST OF TABLES
Table 4.1 Cancer Vaccines: Potential Antigen Targets
Table 5.1 Cancer Vaccines: Pipeline
Table 5.2 Cancer Vaccines: Pipeline (Other Vaccines)
Table 6.1 Dendritic Cell Cancer Vaccines: Pipeline
Table 6.2 Dendreon Corporation: Patent Portfolio
Table 6.3 Dendreon Corporation: Cancer Vaccine Portfolio
Table 6.4 PROVENGE: Current Status of Development
Table 6.5 PROVENGE: Clinical Trials
Table 6.6 PROVENGE: Phase III Clinical Trial Endpoints (NCT00779402, NCT00065442, NCT01133704, NCT00005947)
Table 6.7 PROVENGE: Phase II Clinical Trial Endpoints (NCT01431391, NCT01338012, NCT01487863, NCT00715104)
Table 6.8 PROVENGE: Phase II Clinical Trial Endpoints (NCT01477749, NCT01981122, NCT00901342, NCT01804465)
Table 6.9 PROVENGE: Phase II Clinical Trial Endpoints (NCT00715078, NCT01706458, NCT02159950, NCT00849290, NCT01833208)
Table 6.10 JW CreaGene: Patent Portfolio
Table 6.11 JW CreaGene: Cancer Vaccine Portfolio
Table 6.12 CreaVax-RCC: Clinical Trials
Table 6.13 CreaVax-HCC: Current Status of Development
Table 6.14 CreaVax-HCC: Clinical Trials
Table 6.15 CreaVax-HCC: Clinical Trial Endpoints
Table 6.16 Oncobiomed: Cancer Vaccine Portfolio
Table 6.17 TAPCells: Clinical Trials and Results
Table 6.18 Argos Therapeutics: Patent Portfolio
Table 6.19 Argos Therapeutics: Cancer Vaccine Portfolio
Table 6.20 AGS-003: Current Status of Development
Table 6.21 AGS-003: Clinical Trials
Table 6.22 AGS-003: Clinical Trial Endpoints
Table 6.23 ImmunoCellular Therapeutics: Patent Portfolio
Table 6.24 ImmunoCellular Therapeutics: Cancer Vaccine Portfolio
Table 6.25 ICT-107: Phases of Treatment Regimen
Table 6.26 ICT-107: Current Status of Development
Table 6.27 ICT-107: Clinical Trials
Table 6.28 ICT-107: Clinical Trial Endpoints
Table 6.29 Northwest Biotherapeutics: Patent Portfolio
Table 6.30 Northwest Biotherapeutics: Cancer Vaccine Portfolio
Table 6.31 DCVax-L: Current Status of Development
Table 6.32 DCVax-L: Clinical Trials
Table 6.33 DCVax-L: Clinical Trial Endpoints
Table 6.34 SOTIO: Patent Portfolio
Table 6.35 SOTIO: Cancer Vaccine Portfolio
Table 6.36 DCVAC/PCa: Current Status of Development
Table 6.37 DCVAC/PCa: Clinical Trials
Table 6.38 DCVAC/PCa: Clinical Trial Endpoints (NCT02111577, NCT02105675, NCT02107391)
Table 6.39 DCVAC/PCa: Clinical Trial Endpoints (NCT02107430, NCT02107404, NCT02137746)
Table 7.1 Tumor Cell Cancer Vaccines: Pipeline
Table 7.2 Vaccinogen: Patent Portfolio
Table 7.3 Vaccinogen: Cancer Vaccine Portfolio
Table 7.4 OncoVAX: Current Status of Development
Table 7.5 OncoVAX: Clinical Trials
Table 7.6 OncoVAX: Ongoing Clinical Trials
Table 7.7 OncoVAX: Results of Completed Clinical Trials
Table 7.8 Gradalis: Patent Portfolio
Table 7.9 Gradalis: Cancer Vaccine Portfolio
Table 7.10 Vigil: Current Status of Development
Table 7.11 Vigil: Clinical Trials
Table 7.12 Vigil: Clinical Trial Endpoints (Ovarian Cancer)
Table 7.13 Vigil: Clinical Trial Endpoints (Ewing’s Sarcoma)
Table 7.14 Vigil: Clinical Trial Endpoints (NSCLC)
Table 7.15 Vigil: Clinical Trial Endpoints (Melanoma)
Table 7.16 NewLink Genetics: Patent Portfolio
Table 7.17 NewLink Genetics: Cancer Vaccine Portfolio
Table 7.18 Algenpantucel-L: Clinical Trials
Table 7.19 Algenpantucel-L: Clinical Trial Endpoints
Table 7.20 Tergenpumatucel-L: Clinical Trials
Table 7.21 Tergenpumatucel-L: Clinical Trial Endpoints
Table 8.1 Asterias Biotherapeutics: Cancer Vaccine Portfolio
Table 8.2 AVAX Technologies: Cancer Vaccine Portfolio
Table 8.3 DCPrime: Cancer Vaccine Portfolio
Table 8.4 Heat Biologics: Cancer Vaccine Portfolio
Table 8.5 Immunicum: Cancer Vaccine Portfolio
Table 8.6 XEME Biopharma: Cancer Vaccine Portfolio
Table 9.1 Cancer Vaccines: Funding Instances
Table 9.2 Cancer Vaccines Market: Types of Funding Instances, Pre-2009-2016
Table 10.1 Cancer Vaccines: Partnerships
Table 11.1 Cancer Vaccines: Expected Timelines of Marketed / Late Stage Therapies
Table 11.2 PROVENGE: Target Patient Population
Table 11.3 DCVax-L: Target Patient Population
Table 11.4 AGS-003: Target Patient Population
Table 11.5 DCVAC/PCa: Target Patient Population
Table 11.6 Vigil: Target Patient Population
Table 11.7 AST-VAC1: Target Patient Population
Table 11.8 M-VAX: Target Patient Population
Table 11.9 ICT-107: Target Patient Population
Table 11.10 OncoVAX: Target Patient Population
Table 11.11 MX-225: Target Patient Population
Table 14.1 Global Cancer Incidence: Distribution by Type of Cancer
Table 14.2 Lung Cancer: Estimated New Cases in 2015 (Thousands)
Table 14.3 Breast Cancer: Estimated New Cases in 2015 (Thousands)
Table 14.4 Colorectal Cancer: Estimated New Cases in 2015 (Thousands)
Table 14.5 Cancer Vaccines: Distribution by Type of Vaccine
Table 14.6 Cancer Vaccines: Distribution by Phase of Development
Table 14.7 Cancer Vaccines: Distribution by Phase of Development (Marketed / PIII / PII / PI / Preclinical)
Table 14.8 Cancer Vaccines: Distribution by Therapeutic Area
Table 14.9 Cancer Vaccines: Distribution by Hematological Cancers and Type of Vaccine
Table 14.10 Cancer Vaccines: Distribution by Non-Hematological Cancers and Type of Vaccine
Table 14.11 Cancer Vaccines: Distribution by Type of Donor
Table 14.12 Dendreon Corporation: Revenues, 2010-2013 (USD Million)
Table 14.13 PROVENGE: Historical Sales, 2011-2015 (USD Million)
Table 14.14 Argos Therapeutics: Revenues, 2012-2016 (USD Million)
Table 14.15 Argos Therapeutics: Funding Instances (USD Million)
Table 14.16 ImmunoCellular Therapeutics: Funding Instances (USD Million)
Table 14.17 Northwest Biotherapeutics: Revenue, 2011-2015 (USD Million)
Table 14.18 Northwest Biotherapeutics: Funding Instances (USD Million)
Table 14.19 PPF Group: Revenues, 2011-2015 (EUR Billion)
Table 14.20 Vaccinogen: Funding Instances (USD Million)
Table 14.21 NewLink Genetics: Revenues, 2012-2016 (USD Million)
Table 14.22 NewLink Genetics: Funding Instances (USD Million)
Table 14.23 Cumulative Funding Instances, Pre-2009-2016
Table 14.24 Cumulative Funding Amount, Pre-2009-2016 (USD Million)
Table 14.25 Funding Instances: Distribution by Type, Pre-2009-2016
Table 14.26 Funding Instances: Distribution by Total Amount Invested, Pre-2009-2016 (USD Million)
Table 14.25 Leading Players: Distribution by Number of Funding Instances
Table 14.26 Cancer Vaccines: Cumulative Trend of Partnerships (Pre-2010-2016)
Table 14.27 Cancer Vaccines: Distribution by Type of Partnership
Table 14.28 Cancer Vaccines: Leading Players by Partnerships
Table 14.29 Overall Dendritic Cell and Tumor Cell Cancer Vaccines Market (USD Million), 2016-2030
Table 14.30 Overall Dendritic Cell and Tumor Cell Cancer Vaccine Market: Distribution by Type of Cancer Vaccine (USD Million), 2016-2030
Table 14.31 PROVENGE Sales Forecast, 2016-2030: Conservative Scenario, Base Scenario and Optimistic Scenario (USD Million)
Table 14.32 DCVax-L Sales Forecast, 2017-2030: Conservative Scenario, Base Scenario and Optimistic Scenario (USD Million)
Table 14.33 AGS-003 Sales Forecast, 2018-2030: Conservative Scenario, Base Scenario and Optimistic Scenario (USD Million)
Table 14.34 DCVAC/PCa Sales Forecast, 2020-2030: Conservative Scenario, Base Scenario and Optimistic Scenario (USD Million)
Table 14.35 Vigil Sales Forecast, 2021-2030: Conservative Scenario, Base Scenario and Optimistic Scenario (USD Million)
Table 14.36 AST-VAC1 Sales Forecast, 2022-2030: Conservative Scenario, Base Scenario and Optimistic Scenario (USD Million)
Table 14.37 M-VAX Sales Forecast, 2022-2030: Conservative Scenario, Base Scenario and Optimistic Scenario (USD Million)
Table 14.38 ICT-107 Sales Forecast, 2023-2030: Conservative Scenario, Base Scenario and Optimistic Scenario (USD Million)
Table 14.39 OncoVAX Sales Forecast, 2025-2030: Conservative Scenario, Base Scenario and Optimistic Scenario (USD Million)
Table 14.40 MX-225 Sales Forecast, 2026-2030: Base Scenario (USD Million)
Table 14.41 Dendritic Cell and Tumor Cell Cancer Vaccines Market: Conservative, Base and Optimistic Forecast Scenarios, 2016-2030 (USD Million)

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook